| Identification | Back Directory | [Name]
LGD-3303 | [CAS]
917891-35-1 | [Synonyms]
LGD-3033
LGD-3303; LGD 3303; LGD3303
factory supply LGD-3033 CAS NO.917891-35-1
7H-Pyrrolo[3,2-f]quinolin-7-one, 9-chloro-2-ethyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)- | [EINECS(EC#)]
917891-350-1 | [Molecular Formula]
C16H14ClF3N2O | [MOL File]
917891-35-1.mol | [Molecular Weight]
342.74 |
| Chemical Properties | Back Directory | [Boiling point ]
492.0±45.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Chloroform (Very Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
14.06±0.70(Predicted) | [color ]
Pale Yellow to Light Yellow | [InChI]
InChI=1S/C16H14ClF3N2O/c1-3-11-8(2)14-12(22(11)7-16(18,19)20)5-4-10-15(14)9(17)6-13(23)21-10/h4-6H,3,7H2,1-2H3,(H,21,23) | [InChIKey]
OMXGOGXEWUCLFI-UHFFFAOYSA-N | [SMILES]
N1C2=C(C3C(C)=C(CC)N(CC(F)(F)F)C=3C=C2)C(Cl)=CC1=O |
| Hazard Information | Back Directory | [Description]
LGD-3303 is a selective androgen receptor modulator (SARM), which was originally developed as a means to help treat muscle wasting illnesses, as well as conditions like osteoporosi. It s a nonsteroidal, nonaromatizable androgen receptor ligand that binds to the androgen receptor with high affinity in a radiolabeled to competitive binding assay (Ki=0.9 nM)
| [Uses]
LGD-3303 is used in methods reducing mammographic breast density and/or breast cancer risk comprising the administration of an effective administration of an androgenic agent and an effective amt. of an aromatase inhibitor. LGD-3303 is also used in combination with anti-TWEAK antibodies for treating muscle atrophy. | [Side effects]
LGD 3303 side effects could be an increase in cholesterol as well as an imbalance of your testosterone. Increase in blood pressure is another side effect. |
|
|